The authors of this study propose that both are possible and utilize a biopsychosocial model to explain how one drug can both enhance and impair sexual function
doi:10.1002/lary.26607
Safety assessments were conducted from baseline through end-of-study follow-up, and pharmacokinetic and exploratory assessments were performed at prespecified time points, including serial sampling up to 672 h after the final dose
Abstract Obesity in reproductive-age women is associated with increased risk of cardiometabolic disease, infertility, and pregnancy-related complications affecting both the mother and fetus
These include a personal or family history of medullary thyroid carcinoma, a history of pancreatitis and Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Clinical trials have shown body weight reductions of 15 to 20% in some participants, which explains why these medications have exploded in popularity beyond diabetes treatment (Wilding et al., 2021, New England Journal of Medicine)